journals.asm.org
A single immunization of Borreliella burgdorferi-infected mice with Vanguard crLyme elicits robust antibody responses to diverse strains and variants of outer surface protein C | Infection and Immunity
Borreliella burgdorferi, the primary causative agent of Lyme disease in North America (1, 2), is the most common tick-borne pathogen in the northern hemisphere (3, 4). The American College of Veterinary Internal Medicine recommends that dogs residing in, or near, endemic regions for Lyme disease be screened yearly for exposure to tick-borne pathogens (5). In 2023, the Companion Animal Parasite Council (CAPC) reported that 465,700 dogs in the United States tested positive for antibodies (Abs) to B. burgdorferi. The actual number of positive tests is much higher as only about 1/3 of test results are cataloged by CAPC. Antibiotic therapy generally results in positive clinical outcomes when canine Lyme disease is diagnosed and treated early (5). However, if untreated, transient intermittent lameness, polyarthritis, and potentially fatal nephritis may develop.